SAN DIEGO, Jul 26, 2010 (BUSINESS WIRE) --
Illumina, Inc. (NASDAQ:ILMN) today announced the launch of its TruSeq SBS Sequencing kit that will enable high-quality paired end reads of 150 base pairs (bp), increase the output of high-quality base calls, and enhance throughput to greater than 95 Gigabases (Gb) of high-quality base pairs per run on Illumina's Genome Analyzer (GA) sequencing system. The kit, which the company has commenced shipping broadly, is the first in a series of new kits that will further advance data quality, ease of use and economical sequencing on the company's sequencing platforms. Individual products within the family of TruSeq reagents will be specifically formulated for each Illumina sequencing platform to best leverage the features of that system to provide the highest yield and quality of data.
"At NCGR, we're using TruSeq SBS chemistry to routinely generate over 85% Q30 data for our 100 bp runs, which is a dramatic improvement in both accuracy and output," said Gregory May, President and Chief Operating Officer at the National Center for Genome Resources. "In addition, we're now able to perform paired end reads up to 150 bp on the Genome Analyzer, which will help us greatly in both our de novo sequencing studies as well as our ongoing agriculture sequencing projects."
Coupled with advances in algorithms, the TruSeq SBS Sequencing kit will enable researchers to increase the yield of Q30 base calls and generate approximately 500 million perfect reads per 2x100 bp run, setting a new standard for output of high-quality data from the GA. The yield of perfect reads is an important indicator of a system's overall quality and helps greatly in mapping accuracy, yield and overall coverage of a genome.
"The TruSeq family of reagents is the newest in a long line of sample preparation and chemistry advancements focused on enhancing ease of use, data quality and economical sequencing," said Christian Henry, Senior Vice President and General Manager of Life Sciences at Illumina. "The TruSeq SBS Sequencing kit will provide researchers with even greater accuracy on the Genome Analyzer to generate data with higher mapping rates as well as lower false positive and negative rates. These improvements will materially enhance researchers' ability to paint the truest picture of the genome."
Illumina anticipates following up the release of the TruSeq SBS Sequencing kit with TruSeq Cluster Generation kits and TruSeq Sample Preparation kits for both DNA and RNA applications on the GA later this year. The family of TruSeq reagents will provide Illumina sequencing users with the most optimal workflow and highest quality data possible on the company's platforms.
For more information about Illumina's next-generation sequencing tools, please visit: http://www.illumina.com/?utm_source=various&utm_medium=press_release_07262010&utm_campaign=truseq.
About Illumina
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Sr. Manager, Public Relations
858-882-6822
wgrabill@illumina.com
